These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Karanikolas BD; Figueiredo ML; Wu L Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051 [TBL] [Abstract][Full Text] [Related]
5. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Karanikolas BD; Figueiredo ML; Wu L Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877 [TBL] [Abstract][Full Text] [Related]
6. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals. Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473 [TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]
8. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025 [TBL] [Abstract][Full Text] [Related]
9. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Bryant RJ; Winder SJ; Cross SS; Hamdy FC; Cunliffe VT Prostate; 2008 Feb; 68(3):255-63. PubMed ID: 18095286 [TBL] [Abstract][Full Text] [Related]
10. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810 [TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
12. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874 [TBL] [Abstract][Full Text] [Related]
13. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562 [TBL] [Abstract][Full Text] [Related]
14. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160 [TBL] [Abstract][Full Text] [Related]
16. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Bohrer LR; Chen S; Hallstrom TC; Huang H Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251 [TBL] [Abstract][Full Text] [Related]
17. PC-1/PrLZ contributes to malignant progression in prostate cancer. Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733 [TBL] [Abstract][Full Text] [Related]
18. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071 [TBL] [Abstract][Full Text] [Related]
19. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Dai Y; Ngo D; Jacob J; Forman LW; Faller DV Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222 [TBL] [Abstract][Full Text] [Related]
20. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]